DOI: 10.1177/03000605261488089 ISSN: 0300-0605
Multiomics analysis identifies
RNASET2
as a potential candidate target associated with lung adenocarcinoma
Yue Shi, Jiankun Yang, Fangyu Cai, Jian Huang, Jianing Bi, Kun Wang, Guangyou Wang, Xianglong Kong, Yaoguo Lang, Jian Zhang, Shidong Xu, Hai Xu
Objective
Lung cancer is the leading cause of cancer-related mortality worldwide, with lung adenocarcinoma representing the predominant subtype. The increasing incidence of lung adenocarcinoma underscores the urgent need to establish novel therapeutic targets for clinical intervention.
Methods
We performed Mendelian randomization and colocalization analyses on large-scale lung adenocarcinoma genome-wide association study datasets. Bulk transcriptome and single-cell RNA sequencing were further applied to explore the function of candidate targets and related cell types.
Results
Mendelian randomization revealed that elevated
RNASET2
expression causally reduced the risk of lung adenocarcinoma (odds ratio = 0.817, 95% confidence interval: 0.754–0.885,
p
< 0.001), whereas increased
BTN3A2
expression was associated with an elevated disease risk. Colocalization analysis supported a shared causal variant between
RNASET2
and lung adenocarcinoma (posterior probability of hypothesis 4 = 78.6%). Bulk transcriptome data demonstrated that
RNASET2
was upregulated in tumor tissues and was associated with better prognosis. Single-cell RNA sequencing revealed that macrophages were the predominant cell type expressing
RNASET2
, whereas weak expression was also detected in pulmonary epithelial cells and several other cell populations. There was a trend toward reduced abundance of high
RNASET2
-expressing macrophage subcluster 0 in tumor tissues, whereas low
RNASET2
-expressing subcluster 8 tended to accumulate within tumor lesions. Enrichment analysis of their signature genes suggested opposing biological roles in lung adenocarcinoma progression, which warrants further functional verification.
Conclusions
RNASET2
is closely associated with the occurrence and prognosis of lung adenocarcinoma. Macrophage-expressed
RNASET2
represent a promising candidate molecule for further therapeutic exploration.